Pancreatic adenocarcinoma will be the 2nd cause of death by cancer in Europe in 2030. Pancreatic adenocarcinoma has poor prognosis with an all-stages combined 5-year survival rate below 8%.

Since December 2019, a new coronavirus (Severe Acute Respiratory Syndrome Corona Virus 2, SARS-CoV-2) is responsible of COVID-19 infection with potentially severe respiratory syndrome or even multi-organ failure. An increased risk of severe COVID-19 infection in cancer patients is suggested in several Chinese series. Cancer care structures quickly reorganized to limit high-risk situations (diagnostic procedure, major surgery, cytotoxic poly-chemotherapy) and use alternatives such as on-hold chemotherapy. These reorganizations could be associated with a loss of chance for pancreatic adenocarcinoma.

The aim of this study is to study impact of reorganization of the healthcare system during COVID-19 pandemic on pancreatic adenocarcinoma patients management

Inclusion criteria :

1. aged 18 or over,
2. with pancreatic adenocarcinoma diagnosed by anatomopathological specimen or without biopsy but with suspicion of pancreatic adenocarcinoma in presence of imaging techniques or Ca19.9 level without evidence for neuroendocrine tumor,
3. assessed during multidisciplinary meeting in one participating center between 01/09/2019 and 31/10/2020,
4. accepting to participate to the study,
5. with or without SARS-CoV-2 infection.

Exclusion criteria :

1. with neuroendocrine neoplasia
2. for whom histology showed non pancreatic
3. with cystadenoma or IPMN without invasive adenocarcinoma

Patients with pancreatic adenocarcinoma diagnosed between 01/09/2019 and 31/10/2020.